Medical approach to advanced prostate cancer in older patients

Aging Health

Volumn 4, Issue 5, 2008, Pages 481-494

  Falci, Cris ^a   Brunello, A ^a   Basso, U ^a   Roma, A ^a   Monfardini, Silvio ^b  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

Androgen ablation; Chemotherapy; Elderly

Indexed keywords

ACETYLSALICYLIC ACID; ANTIANDROGEN; ANTIDIABETIC AGENT; BEVACIZUMAB; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; CARBOPLATIN; DIETHYLSTILBESTROL; DOCETAXEL; ERLOTINIB; ESTRAMUSTINE; EULEXINE; FLUTAMIDE; GONADORELIN AGONIST; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; IXABEPILONE; MITOXANTRONE; NAVELBINE; PLACEBO; PREDNISONE; PROSTADIREX; SATRAPLATIN; SEROTONIN UPTAKE INHIBITOR; SORAFENIB; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D; ZOLEDRONIC ACID;

ADVANCED CANCER; ANDROGEN RELEASE; ANEMIA; AREA UNDER THE CURVE; BLOOD TOXICITY; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE NECROSIS; BRAIN ISCHEMIA; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASTRATION; CHILL; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DEHYDRATION; DEPRESSION; DIARRHEA; DIET SUPPLEMENTATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; ELDERLY CARE; ERECTILE DYSFUNCTION; FATIGUE; FLUID RETENTION; FRAILTY SYNDROME; FUNCTIONAL DISEASE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GYNECOMASTIA; HOT FLUSH; HUMAN; HYPERTENSION; INFECTION; INTERMETHOD COMPARISON; JAW DISEASE; LIBIDO DISORDER; LONG TERM CARE; LOW DRUG DOSE; MALE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCLE ATROPHY; MYALGIA; NAIL; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; ORCHIECTOMY; OSTEOPOROSIS; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SINGLE DRUG DOSE; THERAPY DELAY; THROMBOCYTOPENIA; THROMBOEMBOLISM; VOMITING; WATCHFUL WAITING;

EID: 53249113435     PISSN: 1745509X     EISSN: 17455103     Source Type: Journal    
DOI: 10.2217/1745509X.4.5.481     Document Type: Review

References (68)

1. Jernal A, Siegel R, Ward E et al.: Cancer statistics, 2008. CA Cancer J. Clin. 58, 71-96 (2008).
2. Tyrrell CJ, Altwein JE, Klippel F et al.: Comparison of an LH-RH analogue (goeserelin acetate, 'Zoladex'®) with combined androgen blockade in advanced prostate cancer: final survival results of an international multicentre randomized-trial. International Prostate Cancer Study Group. Eur. Urol. 37, 205-211 (2000).
3. Tannock IF, de Wit R, Berry WR et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. Med. 351, 1502-1512 (2004).
4. No authors listed: Immediate versus, deferred treatment for advanced prostate cancer: initial results of the Medical Research Council trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br. J. Urol. 79, 235-246 (1997).
5. Heidenreich A, Aus G, Bolla M et al.: European Association of Urology guidelines on prostate cancer. Eur. Urol. 53, 68-80 (2008).
6. Donelly RJ, Milstead RAV: Zoladex® studies in prostatic and breast cancer. In: LHRH and its analogues: contraception and therapeutic applications, Part 2. Vickery BH, Nestor JJ (Eds). MTP Press, Lancaster, UK 397-407 (1987).
7. No authors listed: Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 355, 1491-1498 (2000).
8. Altwein JE: Complete androgen blockade versus monotherapy. Urology 37, 149-152 (1998).
9. Tyrrell Cj, Kaisary AV, Iversen, P et al.: A randomised comparison of 'Casodex'® (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur. Urol. 33, 447-456 (1998).
10. Hurtado-Coll A, Goldenberg SL, Gleave ME Klotz L: Intermittent androgen suppression in prostate cancer: the Canadian experience. Urology 60, 52-56 (2002).
11. Prapotnich D, Fizazi K, Escudier, B, Mombet A, Cathata, N, Vallancien G: A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur. Urol. 4, 233-239 (2003).
12. Droz JP, Balducci L, Bolla, M et al.: SIOG prostate cancer guidelines proposals in senior adult men. Crit. Rev. Oncol. Hematol. 60, S9, abs IVA (2006).
13. Fossa SD, Slee PH, Brausi M et al.: Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a Phase III study of the European organization for research and treatment of cancer genitourinary group. J. Clin. Omcol. 19, 62-71 (2001).
14. Schellhammer PF, Venner P, Haas GP et al.: Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J. Urol. 157, 1731-1735 (1997).
15. Suzuki H, Okihara K, Miyake et al.: Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. Urology 180, 921-927 (2008).
16. Byar DP, Corle DK.: Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. Natl Cancer Inst. Monogr. 7, 165-190 (1988).
17. Tannock I, Gospodarowicz M, Meakin W et al.: Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J. Clin. Oncol. 7, 590-597 (1989).
18. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR: Osteoporosis in men with prostate: carcinoma receiving androgen-deprivation therapy. Recommendations for diagnosis and therapies. Cancer 100, 892-899 (2004).
19. Guise TA, Oefelein MG, Eastham JA, Cookson MS, Higano CS, Smith MR: Estrogenic side effects of androgen deprivation therapy. Rev. Urology 9, 163-180 (2007).
20. Saad F, Sternberg CN: Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy. Nat. Clin. Pract. Urology 4, S3-13 (2007).
21. Thompson CA, Shanafelt TD, Loprinzi L: Symptom managernent for prostate cancer patients treated with hormonal ablation. The Oncologist 8, 474-487 (2003).
22. Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G: Anemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br. J. Urol. 79, 933-941 (1997).
23. Keating NL, O'Malley AJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 24, 4448-4456 (2006).
24. Holzbeierlein JM, McLaughlin MD, Thrasher JB: Complications of androgen deprivation therapy for prostate cancer. Curr. Opin. Urol. 14, 177-185 (2004).
25. Green HJ, Pakenham KI, Headley BC et al.: Altered cognitive function in men treated for prostate cancer with luteining hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int. 90, 427-433 (2002).
26. Cherrier MM, Rose AL, Higano C: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. J. Urology 170, 1808-1814 (2003).
27. Joly F, Alibhai MH, Galica J et al.: Impact of andmgen deprivation therapy on physical and cognitive function as well as quality of life of patients with nonmetastatic prostate cancer. J Urology 176, 2443-2447 (2005).
28. Ferrucci L, Guralnik JM, Cavazzini C et al.: The frailty syndrome: a critical issue in geriatric oncology. Crit. Rev. Oncol. Hematol. 46, 127-137 (2003).
29. Bylow K, Mohile SG, Stadler WM, Dale W: Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer? Cancer 15, 2604-2613 (2007).
30. Fried LP, Tangen CM, Walston J et al.: Frailty in older adults: evidence for a phenotype. J. Gerontol. A Biol. Sci. Med. Sci. 56, 146-56 (2001).
31. Basch EM, Somerfield MR, Beer TM et al.: American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J. Clin. Oncol, 33, 5313-5318 (2007).
32. Petrylak DP, Tangen CM, Hussain MH et al.: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 7, 1513-1520 (2004).
33. Sava T, Basso U, Porcaro A, Cetto GL: New standards in the chemotherapy of metastatic hormone-refractory prostate cancer. Exp. Rev. Anticancer Ther. 5, 53-62 (2007).
34. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF: Docetaxei plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J. Clin. Oncol. 26, 242-245 (2008).
35. Wildiers H, Highley MS, de Brujn EA, van Osterom AT: Pharmacology of anticancer drugs in the elderly population. Clin. Pharmacokinet. 42, 1213-1242 (2003).
36. Beer TM, Berry W, Wersinger EM, Bland LB: Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years. Clin. Prostate Cancer 2, 167-172 (2008).
37. Chittoor S, Berry W, Loesch, D et al.: Phase II study of low-dose docetaxel/estramustine in elderly patients or patients aged 18-74 years with hormone-refractory prostate cancer. Chittoor: Clin. Genitourin. Cancer 5, 212-218 (2006).
38. Beer TM, Ryan CW, Venner PM et al.: Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J. Clin. Oncol, 25, 669-674 (2003).
39. Beer TM, Lalani AS, Lee S et al.: C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer 112, 2377-2383 (2008).
40. Beer TM, Ryan CW, Venner PM et al.: Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer 112, 326-330 (2007).
41. Picus J, Halabi S, Rini B et al.: The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): Initial results of CALGB 90006. Proc. Am. Sob. Cl. Onc. 22, (2003) (Abstract 1578).
42. Montgomery RB, Nelson PS, Lin D, Ryan CW, Garzotto M, Beer TM: Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer. Cancer 5, 996-1002 (2008).
43. Gross M, Higano, C, Pantuck A et al.: A Phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer 27, 142-149 (2008).
44. Steinbild SM, Ross K, Frost A et al.: A clinical Phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br. J. Can. 3, 1480-1485 (2007).
45. Ohlmann CH, Engelmann UH, Heidenreich A: Second-line chemotherapy with docetaxel for prostate-specific antigen (PSA) relapse in men with hormone-refractory prostate cancer (HRPC) previously treated with docetaxel-based chemotherapy. J. Clin. Oncol. 23, (Abstract 4682).
46. Di Lorenzo G, Figg WD, Fossa SD et al.: Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a Phase 2 study. Eur. Urol. (2008) (Epub ahead of print).
47. Caffo O, Sava T, Comploj E et al.: Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized Phase II trial. BJU Int. (2008) (Epub ahead of print).
48. Caffo O, Sava T, Comploj E et al.: Docetaxel (D) + estramustine (E) as second line chemotherapy afther D alone, for patients (PTS) with hormone-refractory advanced prostate cancer (HRPC). Ann. Oncol. 17, ix 156 (Abstract 487) (2006).
49. Ross RW, Beer TM, Jacobus S et al.: A Phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 112, 521-526 (2008).
50. Nakabayashi M, Sartor O, Jacobus S et al.: Response to docetaxel/ carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU Int. 101, 308-312 (2008).
51. Saad F, Ruether D, Ernst S et al.: Canadian Urologic Oncology Group (CUOG) Phase II multicenter study using docetaxel/prednisone in the second line setting for metastatic hormone-refractory prostate cancer in patients progressing after first line mitoxantrone/prednisone. Proc. Am. Soc. Clin. Oncol. 23, 405s (2005).
52. Michels J, Montemurro T, Kollmannsberger C et al.: First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer (HRPC): does sequence matter? J. Clin. Oncol. 23 (Abstract 4611) (2005).
53. Abratt RP, Brune D, Dimopoulos MA et al.: Randomised Phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Ann. Oncol. 15, 1613-1621 (2004).
54. Sartor AD, Petrylak DP, Witjes JA et al.: Satraplatin in patients with advanced hormone-refractory prostate cancer (HRPC): overall survival (OS) results from the Phase III satraplatin and prednisone against refractory cancer (SPARC) trial. Proc. Am. Soc. Clin. Oncol. 26, 5000 (Abstract 5003) (2008).
55. Rosenberg JE, Weinberg VK, Kelly WK et al.: Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized Phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 110, 556-563 (2008).
56. Saad F, Gleason DM, Murray R et al.: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl Cancer Inst. 96, 879-882 (2004).
57. Body JJ, Coleman R, Clezardin P, Ripamonti C, Rizzoli R, Aapro, M: International society of geriatric oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur. J. Cancer 43, 852-858 (2007).
58. Loblaw DA, Mendelson DS, Talcott JA et al.: American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J. Clin. Oncol. 22, 2927-2941 (2004).
59. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW: Studies of illness in the age. The index of ADL: a standardised measure of biological and psychological function. JAMA 185, 914-919 (1963).
60. Lawton MP, Brody EM: Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9, 179-186 (1969).
61. Chadson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chron. Dis. 40, 373-383 (1987).
62. Miller MD, Paradis CF, Houck PR et al.: Rating chronic medical illness burden in gero-psychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 41, 237-248 (1992).
63. Folstein MF: 'Mini Mental State': a practical method for grading the cognitive state of patients for the clinician. J. Psichiatr Res. 12, 189-198 (1975).
64. Terret C, Albrand G, Droz JP: Geriatric assessment in elderly patients with prostate cancer: Clin. Prostate Cancer 2, 236-240 (2004).
65. Mohile SG, Bylow K, Dale W et al.: A pilot study of the Vulnerable Elders Survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer 109, 802-810 (2007).
66. Saliba D, Elliot M, Rubenstein LZ et al.: The vulnerable elders survey: a tool for identifying vulnerable older people in the community. J. Am. Ger. Soc. 49, 1691-1699 (2001).
67. Adelson KB, Loprinzi CL, Hershman DL: Treatment of hot flushes in breast and prostate cancer. Expert Opin. Pharmacother. 6, 1095-1106 (2005).
68. Loprinzi CL, Michalak JC, Quella SK et al.: Megestrol acetate for the prevention of hot flashes. N. Engl. J. Med. 11, 347-352 (1994).